ArticleApplied biochemistry and biotechnology2026
Modulation of Inflammatory and Apoptotic Pathways by Tamarix Aphylla Essential Oil in TNBS-Induced Colitis: A Focus on Cytokine Balancing, NF-κB, p38 MAPK, and Nrf2 Activation.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Inflammatory Bowel Disease (IBD) refers to the inflammatory disorders of the colon and small intestine. The effect of the essential oil from Tamarix aphylla (TAEO) on inflammation and apoptosis has been investigated using a rat TNBS-induced colitis model. The study utilized macroscopic and histopathological evaluations, cytokine profiling by ELISA, and protein expression assays to assess the effects of TAEO on ulceration, cytokine levels, apoptotic proteins, and anti-apoptotic proteins. Sound experimental groups received several dosages of TAEO (10, 30, and hundred mg/kg) and dexamethasone serving as a comparative control. TAEO significantly reduced mucosal damage in a dose-dependent manner, with dosages of 30 and 100 mg/kg effectively decreasing the ulcer index compared to controls (p < 0.001). It also modulated cytokine profiles, notably reducing TNF-α (p < 0.05 for 30 mg/kg; p < 0.001 for 100 mg/kg), IL-1β, and TGF-β (p < 0.05 for 30 mg/kg; p < 0.001 for 100 mg/kg), while increasing IL-10 at higher doses (p < 0.01 for 30 mg/kg; p < 0.001 for 100 mg/kg). Furthermore, TAEO reduced the expression of pro-apoptotic proteins Bax and caspase-3 (p < 0.001 for both at 100 mg/kg), and enhanced the anti-apoptotic protein Bcl-2. Reductions in NF-κB and p38 MAPK activation were also significant (p < 0.01 and p < 0.001, respectively, for 100 mg/kg). Notably, high-dose TAEO (100 mg/kg) significantly activated the Nrf2 pathway more than dexamethasone (p < 0.001), promoting antioxidant defenses. Histopathological assessments confirmed these findings, showing substantial improvements in tissue architecture and reductions in inflammatory markers. TAEO possesses strong anti-inflammatory, anti-apoptotic, and antioxidant actions in TNBS-induced colitis with high therapeutic potential against IBD. The effects are specific towards higher doses, suggesting a dose-dependent mechanism of action, and justifying further testing.
Indexed as
Identifiers
41489705What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.